NCT02518113

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 2 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).

Conditions

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Interventions

Type	Name	Description
DRUG	LY3039478	Administered orally
DRUG	Dexamethasone	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2015-10-01
• Primary completion: 2018-01-15
• Completion: 2018-01-15
• First posted: 2015-08-07
• Last updated: 2019-09-11
• Results posted: 2019-02-06

Locations

22 sites across 5 countries: United States, France, Germany, Israel, Italy